US Patent

US11541034 — Nitrile-containing antiviral compounds

Method of Use · Assigned to Pfizer Inc · Expires 2041-10-31 · 15y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds and methods for treating coronavirus infections, such as COVID-19, by administering therapeutically effective amounts of the compounds.

USPTO Abstract

The invention relates to compounds of Formula Iâ³wherein R, R1, R2, R3, p, q and qâ² are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

Drugs covered by this patent

Paxlovid (Copackaged) (Nirmatrelvir) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3629`	—	Paxlovid (Copackaged)

Patent Metadata

Patent number: US11541034
Jurisdiction: US
Classification: Method of Use
Expires: 2041-10-31
Drug substance claim: No
Drug product claim: No
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.